

Wood Mark
Form 4
June 26, 2012

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Wood Mark

2. Issuer Name **and** Ticker or Trading
Symbol

BIOMARIN PHARMACEUTICAL
INC [BMRN]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)

C/O BIOMARIN
PHARMACEUTICAL INC., 105
DIGITAL DRIVE

3. Date of Earliest Transaction
(Month/Day/Year)
06/22/2012

____ Director ____ 10% Owner
____X____ Officer (give title ____ Other (specify
below) below)
VP, Human Resources

(Street)

NOVATO, CA 94949

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
____X____ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price		
Common Stock	06/22/2012 ⁽¹⁾	06/22/2012	M		83	A	\$ 17.86	32,447	D
Common Stock	06/22/2012 ⁽¹⁾	06/22/2012	M		937	A	\$ 14.39	33,384	D
Common Stock	06/22/2012 ⁽¹⁾	06/22/2012	M		833	A	\$ 21.51	34,217	D
Common Stock	06/22/2012 ⁽¹⁾	06/22/2012	S		1,853	D	\$ 36.8294 ⁽²⁾	32,364	D

Edgar Filing: Wood Mark - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Stock Option (right to buy) Common Stock	\$ 17.86	06/22/2012 ⁽¹⁾	06/22/2012	M	83	06/17/2009 ⁽³⁾ 12/16/2018	Common Stock 83
Stock Option (right to buy) Common Stock	\$ 14.39	06/22/2012 ⁽¹⁾	06/22/2012	M	937	11/12/2009 ⁽⁴⁾ 05/11/2019	Common Stock 937
Stock Option (right to buy) Common Stock	\$ 21.51	06/22/2012 ⁽¹⁾	06/22/2012	M	833	11/12/2010 ⁽⁵⁾ 05/11/2020	Common Stock 833

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
Wood Mark C/O BIOMARIN PHARMACEUTICAL INC.	VP, Human Resources

105 DIGITAL DRIVE
NOVATO, CA 94949

Signatures

/s/ Laura Randall Woodhead,
Attorney-in-Fact

06/26/2012

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to a Rule 10b5-1 Trading plan executed on August 10, 2011.

The price in Column 4 is a weighted average price. The prices actually received ranged from \$36.48 to \$37.11. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(3) Original option grant vests 6/48th on June 17, 2009 and 1/48th each on the 17th of each month thereafter.

(4) Original option grant vests 6/48th on November 12, 2009 and 1/48th each on the 12th of each month thereafter.

(5) Original option grant vests 6/48th on November 12, 2010 and 1/48th each on the 12th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.